HIV vaccine Ad4-mGag - PaxVax

Drug Profile

HIV vaccine Ad4-mGag - PaxVax

Alternative Names: Ad4 mGag HIV vaccine; Adenovirus 4 HIV mGag vaccine

Latest Information Update: 17 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PaxVax
  • Developer National Institute of Allergy and Infectious Diseases; PaxVax
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 20 Apr 2016 Phase I development is ongoing in USA (PO, capsule & liquid)
  • 01 Oct 2013 Phase-I clinical trials in HIV infections in USA (PO, capsule & liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top